Medical insurance reimbursement conditions and policy explanations for tocilizumab

Tocilizumab, as a monoclonal antibody drug targeting the interleukin-6 receptor (IL-6R), has been widely used in the treatment of autoimmune diseases such as rheumatoid arthritis and systemic juvenile idiopathic arthritis (JIA), and has also shown certain efficacy in the treatment of severe inflammatory storm of COVID-19. In China, tocilizumab has been included in the national medical insurance catalog, but its reimbursement indications and conditions are limited, and not all applications in disease states can receive medical insurance support.

According to the relevant policies of the National Medical Insurance Administration, the scope of medical insurance payment for tocilizumab is currently mainly limited to two clinical indications. The first type is systemic juvenile idiopathic arthritis (sJIA) as a second-line treatment drug, which means that patients must receive ineffective first-line treatment options (such as non-steroidal anti-inflammatory drugs or traditional DMARDs) before they can use tocilizumab and apply for medical insurance reimbursement.

The second category is patients with rheumatoid arthritis (RA), in which the medical insurance requirements are more clear: the diagnosis must be confirmed by a physician, and after receiving traditional DMARDs treatment for 3 to 6 months, if the disease activity does not decrease by 50%, they will be eligible for tocilizumab use and medical insurance payment conditions.

When reimbursing from medical insurance, complete clinical evaluation data must be provided, including rheumatoid factor (RF), anti-CCP antibody levels, ESR, CRP, joint swelling and tenderness and other indicators as support. In some areas, special medical insurance approval may be required. In addition, tocilizumab is currently mainly provided in the form of in-hospital medication. That is to say, patients need to be prescribed by a doctor in a hospital with designated medical insurance qualifications before they can obtain medical insurance settlement. Most medicines purchased at their own expense outside the hospital are not reimbursed.

Although tocilizumab has also shown efficacy in COVID-19, giant cell arteritis and other systemic diseases, the above indications have not yet been included in the national medical insurance reimbursement catalog, and use still requires full self-pay. In the future, as clinical evidence accumulates and the medical insurance catalog is updated, it is expected to expand its medical insurance indications.

Reference materials:https://www.drugs.com/mtm/tocilizumab.html